IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

WAGNER ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP2005/003663

FILED: 7 APRIL 2005

U.S. APPLICATION NO: Not yet known

35 USC §371 DATE: Herewith

FOR: PROTEIN KINASE C INHIBITORS FOR THE TREATMENT OF

AUTOIMMUNE DISEASES AND OF TRANSPLANT REJECTION

MS: Amendment

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references were cited in the international stage search report. Since these references are of record in the instant PCT application PCT/EP2005/003663, copies are not enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis Corporate Intellectual Property One Health Plaza, Building 104 East Hanover, NJ 07936-1080 (862) 778-7909

Date: October 5, 2006

.

Thomas R. Savitsky Attorney for Applicants

Reg. No. 31,661

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. 33714-US-PCT APPLICATION NO. Not yet known APPLICANT WAGNER ET AL. FILING DATE

Group

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE 10/18/94	
	AA	5,545,636	8/13/96	Heath, Jr. et al.	514	214		
	AB			1				
	AC							
	AD							
	AE							
	AF							
	AG							
	АН							
	AI							
	AJ							
	AK							
	AL							
			FOREIG	IN PATENT DOCUMENTS	•			
		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN YES	SLATION NO
	АМ	03/082859	10/9/03	wo		******		
	AN	03/104222	12/18/03	WO				
	AO	98/11105	3/19/98	wo				
	AP	0 470 490	2/12/92	EP				
-	AQ							
		OTHER DOO	CUMENTS	(Including Author, Title, Date, F	ertinent pages, l	Etc.)		
	AR			Potential of Protein Kinase ol. 38, pp. 135-147, (1993)		agents and Ad	tions,	
	Nixon J S et al., "Novel, potent and selective inhibitors of protein kinase C show oral anti-inflamm AS activity:, Drugs Under Experimental And Clinical Research, Bioscience Ediprint Inc., Vol. 17, no. 389-393, (1991).							nmatory o. 8, pp.
					hihidaya" Cyaa	of Online on On	Th	noutio
	АТ	Harris W et al., "Rece Patents, United Kingo		nents in protein kinase C in no. 1, pp. 63-68, (1997).	nibitors , ⊏xpe	ert Opinion On	nera	ipeulic

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.